Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Available-for-Sale Debt Securities - Amortized Cost

Available-for-Sale Debt Securities - Amortized Cost at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Biogen logo
BiogenBIIB
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's available-for-sale debt securities - amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's available-for-sale debt securities - amortized cost?
BioMarin Pharmaceuticals (BMRN) reported available-for-sale debt securities - amortized cost of $3.07B in Q1 2026.
How has BioMarin Pharmaceuticals's available-for-sale debt securities - amortized cost changed year-over-year?
BioMarin Pharmaceuticals's available-for-sale debt securities - amortized cost increased by 73.1% year-over-year, from $1.78B to $3.07B.
What is the long-term trend for BioMarin Pharmaceuticals's available-for-sale debt securities - amortized cost?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's available-for-sale debt securities - amortized cost has grown at a 8.8% compound annual growth rate (CAGR), from $1.35B to $2.05B.